A PROSPECTIVE STUDY OF PRE-TREATMENT NEUTROPHIL-TO-LYMPHOCYTE RATIO PROGNOSTICATE POOR SURVIVAL OUTCOMES AND ADVANCED TUMOR STAGING IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER IN A TERTIARY CARE CENTER.

Author:

Sharma Pritam1,Panchumarthi U Chowdary2,Devashish Choubey3,Reddy Avinash1,Kumar E Muneendra2,Chidrawar Yogendra2

Affiliation:

1. Department of Urology,AJIMS,Mangalore,Karnataka,India

2. Department of Urology,AJIMS,Mangalore,Karnataka,India.

3. Department of Urology, Father Muller Medical College, Mangalore, Karnataka,India

Abstract

Background:We aim to determine the prognostic value of neutrophil-to-lymphocyte ratio (NLR) in patients undergoing radical cystectomy for UCB,in particularly looking at the disease specific survival and overall survival.This will allow us to better identify more suitable candidates for RC or other neoadjuvant or adjuvant therapies. Methods:This is retrospective study that includes 91 patients that underwent RC for UCB between Jan 2006 to Dec 2015. We excluded 39 patients due to incomplete follow up and neoadjuvant chemotherapeutic treatment. All patients had histological proven UCB via transurethral resection of bladder tumor (TURBT).All patients had undergone staging scans with computed tomographies of the thorax,abdomen and pelvis to confirm the extent of disease.All patients underwent RC and bilateral standard pelvic lymphadenectomies and achieve clear margins on final histology. Outcomes we recorded are Median Disease – specific survival and Median overall survivals. Results: The Median Disease – specific survival for patients with NLR ≥ 2.7 was 20.4 months and with NLR < 2.7 was 59.9 months.The Median overall survival for patients with NLR ≥ 2.7 was 21.1 months and with NLR < 2.7 was 58.2 months. Conclusions:These results suggested that NLR could be a novel preoperative factor to stratify and identify patients who might benefit from multimodal therapies in the treatment of UCB.

Publisher

World Wide Journals

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3